Bejel laboratory findings: Difference between revisions
m (Changes made per Mahshid's request) |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Bejel}} | {{Bejel}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
{{CMG}} | {{CMG}} | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
===Syphilis Serology=== | |||
Nontreponemal (reagin) Test | ====Nontreponemal (reagin) Test==== | ||
* Treponemal (specific) Test | * Treponemal (specific) Test | ||
* Rapid plasma reagin (RPR) test | * [[Rapid plasma reagin]] ([[RPR]]) test | ||
* Venereal Disease Research Laboratory (VDRL) test | * Venereal Disease Research Laboratory (VDRL) test | ||
* Toluidine red unheated serum test (TRUST) | * [[Toluidine red unheated serum test]] ([[TRUST]]) | ||
Treponemal (specific) Test | ====Treponemal (specific) Test==== | ||
* Rapid plasma reagin (RPR) test | * Rapid plasma reagin (RPR) test | ||
* Venereal Disease Research Laboratory (VDRL) test | * Venereal Disease Research Laboratory (VDRL) test | ||
* Toluidine red unheated serum test (TRUST) | * Toluidine red unheated serum test (TRUST) | ||
* Fluorescent treponemal antibody-absorption (FTA-ABS) test | * [[Fluorescent treponemal antibody-absorption]] ([[FTA-ABS]]) test | ||
* Treponema pallidum immobilization (TPI) test | * Treponema pallidum immobilization ([[TPI]]) test | ||
* Treponema pallidum particle agglutination assay (TPPA) | * Treponema pallidum particle agglutination assay (TPPA) | ||
* Enzyme immune assay (EIA) or enzyme-linked immunosorbent assay (ELISA) | * Enzyme immune assay ([[EIA]]) or enzyme-linked immunosorbent assay (ELISA) | ||
* Chemiluminescence immunoassay | * [[Chemiluminescence immunoassay]] | ||
* Chromatographic point of contact (POC) tests | * Chromatographic point of contact (POC) tests | ||
Serologic tests for syphilis include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test. | Serologic tests for [[syphilis]] include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test. | ||
Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines | Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines | ||
Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment. | Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 35: | Line 33: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Infectious skin diseases]] | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 17:11, 18 September 2017
|
Bejel Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bejel laboratory findings On the Web |
|
American Roentgen Ray Society Images of Bejel laboratory findings |
|
Risk calculators and risk factors for Bejel laboratory findings |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Laboratory Findings
Syphilis Serology
Nontreponemal (reagin) Test
- Treponemal (specific) Test
- Rapid plasma reagin (RPR) test
- Venereal Disease Research Laboratory (VDRL) test
- Toluidine red unheated serum test (TRUST)
Treponemal (specific) Test
- Rapid plasma reagin (RPR) test
- Venereal Disease Research Laboratory (VDRL) test
- Toluidine red unheated serum test (TRUST)
- Fluorescent treponemal antibody-absorption (FTA-ABS) test
- Treponema pallidum immobilization (TPI) test
- Treponema pallidum particle agglutination assay (TPPA)
- Enzyme immune assay (EIA) or enzyme-linked immunosorbent assay (ELISA)
- Chemiluminescence immunoassay
- Chromatographic point of contact (POC) tests
Serologic tests for syphilis include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test.
Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment.